56 avsnitt

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast PeerView

    • Vetenskap

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Neal D. Shore, MD, FACS - Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum

    Neal D. Shore, MD, FACS - Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DME865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.

    Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported through educational grants from Bristol Myers Squibb, Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).

    Disclosure information is available at the beginning of the video presentation.

    • 1 tim. 23 min
    Alicia K. Morgans, MD, MPH, Neal D. Shore, MD, FACS - Treatment Advances and Individualized Therapeutic Strategies in Prostate Cancer: Expert Insights on Key Evidence, Practical Tips for Personalized Therapy, and Clinical Integration Approaches

    Alicia K. Morgans, MD, MPH, Neal D. Shore, MD, FACS - Treatment Advances and Individualized Therapeutic Strategies in Prostate Cancer: Expert Insights on Key Evidence, Practical Tips for Personalized Therapy, and Clinical Integration Approaches

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CJD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until April 24, 2025.

    Treatment Advances and Individualized Therapeutic Strategies in Prostate Cancer: Expert Insights on Key Evidence, Practical Tips for Personalized Therapy, and Clinical Integration Approaches

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Novartis Pharmaceuticals Corporation.

    Disclosure information is available at the beginning of the video presentation.

    • 59 min
    Bradley J. Monk, MD, FACS, FACOG - Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

    Bradley J. Monk, MD, FACS, FACOG - Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.

    Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.

    Disclosure information is available at the beginning of the video presentation.

    • 59 min
    Kathleen N. Moore, MD, MS - Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

    Kathleen N. Moore, MD, MS - Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.

    Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.

    Disclosure information is available at the beginning of the video presentation.

    • 1 tim. 17 min
    Matthew D. Galsky, MD - Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

    Matthew D. Galsky, MD - Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JSQ865. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.

    Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Matthew D. Galsky, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer and Seagen Inc.
    Grant/Research Support from Bristol Myers Squibb and Merck & Co., Inc.


    Faculty/Planner
    Shilpa Gupta, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics (Seagen Inc.).
    Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.; and Seattle Genetics (Seagen Inc.).
    Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle Genetics (Seagen Inc.).


    Faculty/Planner
    Andrea Necchi, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen Inc.
    Grant/Research Support from Bristol Myers Squibb; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    • 1 tim. 30 min
    Prof. Laurence Albiges, MD, PhD - Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors and Preparing for Innovative Delivery Approaches in the Clinic

    Prof. Laurence Albiges, MD, PhD - Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors and Preparing for Innovative Delivery Approaches in the Clinic

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 7, 2025.

    Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported through an educational grant from Bristol Myers Squibb.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    • 24 min

Mest populära poddar inom Vetenskap

Dumma Människor
Acast - Lina Thomsgård och Björn Hedensjö
I hjärnan på Louise Epstein
Sveriges Radio
Vetenskapsradion Historia
Sveriges Radio
P3 Dystopia
Sveriges Radio
A-kursen
Emma Frans och Clara Wallin
Bildningspodden
Anekdot